These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1285694)

  • 1. [Methodological problems of prevention/regression trials of atherosclerosis].
    Sassano P; Benghozi R
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():139-41. PubMed ID: 1285694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is regression of atherosclerosis possible?].
    Thomas D; Richard JL; Emmerich J; Bruckert E; Delahaye F
    Arch Mal Coeur Vaiss; 1992 Oct; 85 Spec No 3():47-57. PubMed ID: 1296545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models and the study of atherosclerosis.
    Vesselinovitch D
    Arch Pathol Lab Med; 1988 Oct; 112(10):1011-7. PubMed ID: 3052351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging.
    Corti R; Osende JI; Fallon JT; Fuster V; Mizsei G; Jneid H; Wright SD; Chaplin WF; Badimon JJ
    J Am Coll Cardiol; 2004 Feb; 43(3):464-73. PubMed ID: 15013132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surrogate endpoints and newer risk markers in atherosclerosis management.
    Ballantyne CM
    Am J Manag Care; 2001 May; 7(5 Suppl):S144-7. PubMed ID: 11383376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plaque-associated immune reactivity as a tool for the diagnosis and treatment of atherosclerosis.
    Harrison DC; Calenoff E; Chen FW; Parmley WW; Khaw BA; Ross R
    Trans Am Clin Climatol Assoc; 1992; 103():210-7. PubMed ID: 1413381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression.
    Marchioli R; Prieto JC; Tognoni G
    Clin Trials Metaanal; 1994 Oct; 29(2-3):139-76. PubMed ID: 10150224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atherosclerosis and brain circulation].
    Sánchez-Pérez RM; Moltó JM; Medrano V; Beltrán I; Díaz-Marín C
    Rev Neurol; 1999 Jun 1-15; 28(11):1109-15. PubMed ID: 10390785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of trials on regression of atheromatous lesions with hypolipemic drugs].
    Coste P; Durrieu C; Besse P
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():189-94. PubMed ID: 1285702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of experimental models for the development of clinical trials on thromboatherosclerosis.
    Fuster V; Ip JH; Badimon L; Badimon JJ; Stein B; Chesebro JH
    Circulation; 1991 Jun; 83(6 Suppl):IV15-25. PubMed ID: 1645625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherosclerosis and thrombosis: lessons from animal models.
    Badimon L
    Thromb Haemost; 2001 Jul; 86(1):356-65. PubMed ID: 11487025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beyond cholesterol levels: new therapeutic indications of statins].
    De Luca N
    Recenti Prog Med; 2001; 92(7-8):429-32. PubMed ID: 11475783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regression of atherosclerosis lesions].
    Weber G; Resi L; Tanganelli P
    Wien Klin Wochenschr; 1989 Oct; 101(20):698-702. PubMed ID: 2686177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regression of coronary arteriosclerosis with hypolipidemic treatment, myth or reality?].
    Lahoz C; Monereo A; Mostaza JM; de Oya M
    Rev Clin Esp; 1992 Nov; 191(7):380-4. PubMed ID: 1475466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Secondary prevention of atherosclerosis: effects on coronary plaques and on myocardial ischemia].
    Douard H; Chevalier L; Bordier P; Broustet JP
    Rev Prat; 1995 Nov; 45(17):2183-9. PubMed ID: 8571044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy.
    Corti R
    Pharmacol Ther; 2006 Apr; 110(1):57-70. PubMed ID: 16445985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research priorities for intracranial atherosclerotic diseases.
    Qureshi AI; Taylor RA
    J Neuroimaging; 2009 Oct; 19 Suppl 1():39S-42S. PubMed ID: 19807858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
    Hof RP; Rüegg UT
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plaque progression and regression in atherothrombosis.
    Ibanez B; Vilahur G; Badimon JJ
    J Thromb Haemost; 2007 Jul; 5 Suppl 1():292-9. PubMed ID: 17635739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rheumatoid arthritis, inflammation, and atherosclerosis].
    Hürlimann D; Enseleit F; Ruschitzka F
    Herz; 2004 Dec; 29(8):760-8. PubMed ID: 15599672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.